SIRT1 and atherosclerosis: In addition, a novel DPP-4 inhibitor anagliptin, was investigated as a potential therapeutic in atherosclerosis, and its treatment improved TNF- α, IL6, and MCP-1 secretion in VSMC, reduced telomerase activity, and reversed upregulated SIRT1 in IL-1 β treated cells.